{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:50:53Z","timestamp":1786996253646,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.revmed.2020.05.026","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T01:50:15Z","timestamp":1594691415000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulants oraux directs\u00a0: dans quelles indications\u00a0? Lequel prescrire\u00a0? Pour ou contre chez les personnes fragiles et dans les situations atypiques\u00a0? Quelle surveillance et gestion des accidents h\u00e9morragiques\u00a0?"],"prefix":"10.1016","volume":"41","author":[{"given":"C.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Le Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De Moreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lacut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.05.026_bb0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.05.026_bb0010","first-page":"e125","volume":"140","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmr.2019.01.003","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l\u2019adulte \u2013 version longue","volume":"36","author":"Sanchez","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.revmed.2020.05.026_bb0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.annfar.2011.10.008","article-title":"Pr\u00e9vention de la maladie thromboembolique veineuse postop\u00e9ratoire. Actualisation 2011. Texte court","volume":"30","author":"Samama","year":"2011","journal-title":"Ann Fr Anesth R\u00e9animation"},{"key":"10.1016\/j.revmed.2020.05.026_bb0025","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the re-model randomised trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.05.026_bb0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.026_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.revmed.2020.05.026_bb0040","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0045","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (record4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.026_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.026_bb0055","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0060","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0065","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (advance-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.026_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein\u2013DVT dose-ranging study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.026_bb0080","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.05.026_bb0095","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.026_bb0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/VHRM.S50543","article-title":"Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review","volume":"10","author":"Gomez-Outes","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.revmed.2020.05.026_bb0105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijcard.2014.08.136","article-title":"Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis","volume":"177","author":"Vedovati","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ Can Med Assoc J"},{"key":"10.1016\/j.revmed.2020.05.026_bb0120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2020.05.026_bb0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1160\/TH16-03-0205","article-title":"Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France","volume":"116","author":"Delluc","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.05.026_bb0140","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorisation of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.05.026_bb0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0150","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomised trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2018-99-118808","article-title":"Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial","volume":"132","author":"McBane","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.05.026_bb0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0165","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0170","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS\u2013cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.revmed.2020.05.026_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0180","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0185","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0190","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jdmv.2018.12.065","article-title":"Traitement du syndrome des antiphospholipides, place des anticoagulants oraux directs","volume":"44","author":"Benhamou","year":"2019","journal-title":"JMV-J M\u00e9decine Vasc"},{"key":"10.1016\/j.revmed.2020.05.026_bb0200","series-title":"International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress","article-title":"Abstract LB 01.5","author":"Male","year":"2019"},{"key":"10.1016\/j.revmed.2020.05.026_bb0205","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis","volume":"132","author":"Sharma","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2020.05.026_bb0210","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomised trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.revmed.2020.05.026_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-12-21","article-title":"Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants","volume":"12","author":"Geldhof","year":"2014","journal-title":"Thromb J"},{"key":"10.1016\/j.revmed.2020.05.026_bb0220","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","article-title":"The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight\u2014a systematic literature review","volume":"106","author":"De Caterina","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17474086.2018.1517040","article-title":"Anticoagulation at the extremes of body weight: choices and dosing","volume":"11","author":"McCaughan","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0230","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.05.026_bb0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective dresden NOAC registry (NCT01588119)","volume":"262","author":"Tittl","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2015.09.046","article-title":"Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation","volume":"117","author":"Del-Carpio Munoz","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"Direct oral anticoagulants in patients with liver cirrhosis: a systematic review","volume":"170","author":"Hoolwerf","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.revmed.2020.05.026_bb0250","series-title":"Les anticoagulants en France en 2014: \u00e9tat des lieux, synth\u00e8se et surveillance","volume":"78","author":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9","year":"2014"},{"key":"10.1016\/j.revmed.2020.05.026_bb0255","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.05.026_bb0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2020.05.026_bb0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomised controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2396987317719364","article-title":"European stroke organisation guideline for the diagnosis and treatment of cerebral venous thrombosis \u2013 endorsed by the European academy of neurology","volume":"2","author":"Ferro","year":"2017","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.revmed.2020.05.026_bb0275","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomised clinical trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0280","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non\u2013vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0285","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomised evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.05.026_bb0290","first-page":"391","article-title":"Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French working group on perioperative haemostasis (GIHP) \u2013 september 2016","volume":"37","author":"Albaladejo","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.revmed.2020.05.026_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/VHRM.S191208","article-title":"Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study \u2013 data from the registry of patients on non-vitamin K oral anticoagulants (REGINA)","volume":"15","author":"Monelli","year":"2019","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.revmed.2020.05.026_bb0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0038-1642622","article-title":"Novel anticoagulant treatment for pulmonary embolism with direct oral anticoagulants phase 3 trials and clinical practice","volume":"35","author":"Tromeur","year":"2018","journal-title":"Semin Interv Radiol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:22Z","timestamp":1759336942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320302186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0248866320302186"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.05.026","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulants oraux directs\u00a0: dans quelles indications\u00a0? Lequel prescrire\u00a0? Pour ou contre chez les personnes fragiles et dans les situations atypiques\u00a0? Quelle surveillance et gestion des accidents h\u00e9morragiques\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}